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proposed that the stimulation of erythropoietin receptors by ESAs can lead to increased angiogenesis [5, 6] , tissue-protective effect [5] , lymphangiogenesis [7] and tumor growth [7] .
One of the aforementioned studies reported an increased risk of cancer-related mortality among chronic kidney disease (CKD) patients with a prior history of cancer using darbepoetin compared with the placebo users [8] . Although both Kidney Disease: Improving Global Outcomes (KDIGO) and the U.S. Food and Drug Administration (FDA) issued warnings regarding the use of ESAs in patients with a high risk of cancer, only one study to our current knowledge has evaluated the association between ESAs and the incidence of a novel cancer diagnosis in CKD stage 4 and 5 patients [9, 10] . This retrospective study reported no significant increased risk of developing cancer with ESA use [10] . Unfortunately, this study was based on voluntary reporting by facilities, which in turn leads to various biases. Most studies were conducted among non-ESRD patients or with cancer-related anemia. Because cancer incidence was found to be higher in CKD patients than in a non-CKD population [11] [12] [13] , and due to the fact ESAs are routinely used in the ESRD population, appraising the association between ESAs and cancer in this population is relevant in clinical practice.
The purpose of this study was to evaluate the association between ESAs and the risk of incident cancer in a population of ESRD patients receiving chronic dialysis therapy.
M A T E R I A L S A N D M E T H O D S

Study population and data sources
This retrospective nested case-control study was conducted by linking data from the Canadian Organ Replacement Registry (CORR) and the Régie de l'assurance maladie du Québec (RAMQ). CORR is a Canadian database that collects information longitudinally specifically on ESRD patients receiving renal replacement therapy in all centers with patients undergoing dialysis across Canada. The database includes demographic information, comorbidities, hemodialysis clinical data, outcomes-related data (e.g. death and kidney transplantation) and profiles of all relevant institutions.
RAMQ is the universal health care insurance in the province of Quebec, Canada. All Quebec residents, with the exception of First Nations and military staff, are covered for medical and hospital services by RAMQ. The RAMQ administrative database for reimbursement of medical claims includes all medical visits, diagnostic codes [using International Classification of Diseases (ICD), Ninth or Tenth Edition] and medical procedures during in-and outpatient encounters. This database also contains the hospital discharge summaries' database (Med-Echo), the date of admission and discharge, primary and secondary diagnoses (coded in ICD-9 or ICD-10 after 2006) and all procedures performed during a patient's hospital stay. The validity of discharge summary data in Quebec was evaluated for various components and was subsequently found to be very reliable [14] [15] [16] [17] . RAMQ also provides a provincial drug plan for patients !65 years of age, individuals on welfare and workers not insured by a private insurance company (87% of ESRD patients in our cohort).
Study cohort
Cases and controls were systematically selected from a preestablished incident dialysis (including both peritoneal dialysis and hemodialysis) cohort. A nested case-control approach is often the best option in pharmacoepidemiology, as it allows for a clearer definition of the drug's exposure, which may vary over time. As described in a previous article, all adult patients who began chronic dialysis treatment between 1 January 2001 and 31 December 2007 were included [18] . This study included patients that were identified from both data sources (CORR and RAMQ). Using a 2-year look-back period before the first dialysis code after January 2001, we excluded patients who had dialysis prior to 1 January 2001, who had a prior kidney transplant, who had a prior cancer diagnosis or those who had <90 days of dialysis following the initiation of dialysis. These exclusion criteria are meant to ensure that our cohort includes only incident chronic dialysis patients with no known history of cancer. Patients included in the study were followed from initiation of dialysis to kidney transplantation, cancer diagnosis, mortality or the end of the study period.
Cancer definition (case)
Cases involving cancer were defined as patients having at least one hospitalization or outpatient medical record with a primary diagnosis for cancer (ICD-9 codes: 140-209; ICD-10 codes: C00-C97). These codes correspond to all types of malignant tumors from all body tissues, except benign tumors and carcinomas in situ. The date of the first diagnosis of cancer was considered the index date. In order to assess exposure to ESAs, we included cases with patients exclusively enrolled in the RAMQ drug plan between 9 and 6 months prior to their index date, as drug data were not accessible for patients covered by private insurance.
Control selection
We utilized incidence density sampling to select the controls. They were matched by various factors, including gender, a <5-year age difference and a <90-day period differentiation from the start of follow-up. In terms of selected cases, control subjects had to be on the RAMQ plan between 9 and 6 months prior to their index date. Under this sampling methodology, a patient selected as a control subject can at any point in the study be at risk of becoming a case later in the study and can be subsequently selected as a control several times for different cases. For each case, 10 controls were selected at random from all of the potential matched controls. If a case had <10 controls, all the members of the risk set were selected.
Exposure definition
Our primary exposure definition was identified as a categorical exposure to ESAs (epoetin alfa and darbepoetin alfa) 9 to 6 months before the index date (first diagnosis of cancer). As recommended by the monography and prior studies, we converted dosages of epoetin alfa to darbepoetin alfa using a ratio of 200 IU: 1 mg [19] . Because the expected effect of ESAs is observed over a long period of time and to further minimize protopathic bias, we decided to calculate the average weekly dose of darbepoetin alfa (or equivalent) received by each patient between 9 and 6 months before the index date. Therefore, the use of ESAs in the 6 months prior to the index date was not considered, as it may be the consequence of cancer and not necessarily the initial cause. Exposure was divided into four mutually exclusive categories: unexposed, low dose (>0-<30 mg/week), moderate dose (!30-<70 mg/week) and high dose exposure (!70 mg/week). These categories were determined according to the average weekly dose in the control group and the recommended doses indicated by KDIGO [9] . In the case of overlapping ESA dispensing periods (when dispensing a new prescription occurred before the preceding period was terminated), we considered the dose of the new ESA. Because this information was not obtainable, no distinction could be determined between administration routes (subcutaneous or intravenous).
Covariates
We carefully selected potential confounders based on previously collected clinical knowledge. Upon hemodialysis initiation, we measured the following covariates: demographic variables (RAMQ), body mass index (BMI; CORR), ethnicity (CORR), smoking status (CORR), dialysis modality at initiation (RAMQ) and laboratory data (CORR). To identify comorbidities, we used ICD-9 codes in the RAMQ claims database in the 2 years prior to hemodialysis initiation (see Table 1 for the list of comorbidities). Laboratory data taken into consideration included serum albumin levels, hemoglobin levels and estimated glomerular filtration rate (eGFR) using the four-variable Modification of Diet in Renal Disease equation [20] .
Statistical analysis
The continuous variables were expressed as either the mean and standard deviation (SD) or the median and interquartile range (IQR). Comparisons of characteristics between cases and controls were completed using the Student's t-test and/or the chi-squared test as appropriate. Cancer rates and their subsequent 95% confidence intervals (CIs) were estimated using Poisson distribution. Odds ratios (ORs) indicating an association between ESA usage and cancer incidence were estimated using multivariable conditional logistic regression. The ORs were adjusted for demographics, comorbidities and laboratory data (all variables are listed in Table 1 ). When laboratory data were missing, we used a multiple imputation method (five imputations). We also performed a dose-response analysis between the mean weekly dose of ESA and cancer incidence using restricted cubic splines [21] . Cubic spline models fit the dose-response curve using a cubic polynomial function within mutually exclusive dose intervals and then an impose curve joins at the boundaries to generate a smooth continuous curve [22] . For this analysis, individuals with extreme ESA levels (more than 2 SD from the log-transformed mean of ESA) were excluded to reduce the influence of extreme values. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Sensitivity analyses
Three different sensitivity analyses were completed. For the first analysis, we conducted all analyses using a ratio of 300 IU: 1 mg when converting doses of epoetin alfa to darbepoetin alfa, as suggested by several studies [23, 24] . During the second analysis, we considered an exposition window for ESA between 15 and 12 months before the index date, as opposed to 9 and 6 months from before. Finally, we conducted a complete case analysis (without imputation of missing values). For all sensitivity analyses, models were adjusted for the same set of variables included in the principal analysis.
Ethical considerations
We obtained ethics approval for this study from the Government of Québec ethics' committee (Commission d'accès a l'information-CAI) and from the Maisonneuve-Rosemont Hospital ethics' committee.
R E S U L T S
We identified 4574 patients initiating dialysis treatment between 2001 and 2007, all of whom had not been diagnosed with cancer in the two preceding years. At cohort entry, the median age of patients was 66.0 years (IQR 55.0-74.0), and 40.8% of our subjects were women. The median duration for follow-up was 1.8 years (IQR 0.9-3.1). We identified 773 new cases of cancer, leading to an overall incidence rate of 7.8 cancer Values given as mean 6 SD unless otherwise indicated. We used a ratio of 200 IU: 1 mg when converting doses of epoetin alfa to darbepoetin alfa. Units conversion: albumin, multiply by 10 to convert g/dL to g/L; hemoglobin, multiply by 10 to convert g/dL to g/L. incidences per 100 patient-years (95% CI 7.2-8.3). We excluded 354 cases of cancer for the following reasons: 232 subjects had <6 months of follow-up prior to the index date, 120 subjects were not covered by the drug plan insurance and 2 subjects had no eligible control. Therefore, 419 cases of cancer were included in the final nested case-control analysis. The characteristics of both cases and controls are presented in Table 1 . The majority of patients were Caucasian (90.0% of cases, 85.9% of controls). The comorbidity profile was similar between cases and controls, with an exception for subjects with hyperlipidemia, which was found to be less frequent among cases (57.3% in cases versus 63.3% in controls). More than 88% of the patients in our study cohort were on an ESA. Cases developed cancer after a median time of 1.8 years (IQR 1.0-2.8) . Details on the various types of cancer among cases are displayed in Table 2 .
Risks of cancer correlated with each ESA exposure category and other covariates are presented in Figure 1 shows the smoothed dose-response curves for the risk of cancer as a function of weekly dose of ESA. We can observe that the risk began to increase at a weekly dose of 25 mg and then becomes statistically significant at a weekly dose of 50 mg. For all sensitivity analyses (using a converting ratio of 300 IU: 1 mg, exposition window between 15 and 12 months and without imputation of missing values), results were similar to the main analysis (see Table 4 ).
D I S C U S S I O N
The reported evidence describing the association between ESA use and the development of cancer in patients with kidney failure is scarce. Only one cross-sectional study formerly ascertained the association between the use of ESAs and the risk of cancer incidence among CKD stage 4 and 5 patients [10] . Similarly, the landmark Trial to Reduce Cardiovascular Events with Aranesp Therapy trial did not show any difference in cancer-related events between patients receiving darbepoetin alfa and patients receiving the placebo agent [8] . Our results suggest an association between ESA use and the occurrence of new cancer among chronic dialysis patients. From our findings, this increased risk of cancer appears to be dose-related. While FIGURE 1: Dose-response analysis using cubic spline. We used a ratio of 200 IU: 1 mg when converting doses of epoetin alfa to darbepoetin alfa.
low and moderate doses were not correlated with a higher likelihood of new-onset malignancies, the dose-response analysis depicted an increment in risk starting at a mean weekly dose of 50 mg.
The bulk of evidence pertaining to cancer and ESA administration comes from the non-ESRD population. Most randomized trials on this subject have studied the effect of ESAs on survival as a primary outcome in non-ESRD patients with a cancer-related anemia, showing an increased mortality associated with use of ESAs. The BEST study, which included 939 patients with breast cancer receiving chemotherapy, was terminated prematurely because of a higher risk of mortality in the group treated with epoetin alfa [2] . Likewise, the Primary Prevention Parameters Evaluation (PREPARE) study revealed a seemingly higher risk of mortality in the group receiving darbepoetin alfa [4] . Moreover, the randomized trial by Blohmer et al. [25] did not find any significant difference in the survival of 257 patients with cervical cancer receiving chemotherapy when comparing epoetin alfa to the placebo. Cancer progression was examined as a secondary outcome in most oncology trials. One randomized study conducted on patients with head and neck cancer with anemia undergoing radiotherapy suggested a higher risk of tumor progression with ESA exposure [26] . Recent meta-analyses summarizing the available evidence suggest that ESAs may have no effect on overall tumor progression [27] [28] [29] . These conflicting findings can be explained by heterogeneity with respect to the study population (type of cancer), hemoglobin target and ESA dose. Notably, hemoglobin targets were higher in earlier studies compared with that of current practice. These discrepancies can also be justified by differences in response to ESA modulated by the specific type of tissue involved or stage of cancer [30, 31] . Several potential mechanisms exist by which ESAs could increase the risk of cancer. ESAs are known to increase angiogenesis [5, 6] , tissue-protective effect [5] , lymphangiogenesis [7] , tumor growth [7] and erythropoiesis [7] . Some studies have indicated that CKD may be associated with a higher risk of cancer [11, 12] . Other postulated contributing factors include chronic infection in the urinary tract, a weakened immune system, retention of carcinogenic compounds, and nutritional deficiencies [11, 12] . From this it can be deduced that ESAs can potentiate the risk in the CKD patient population.
One of the main strengths of our study is our sample size. It comprises a large population-based chronic dialysis cohort in a universal health care setting. The capture of cancer events in the entire ESRD population of Quebec has enabled us to control for numerous potential confounders, including smoking. However, our study is not without limitations. The allegedly harmful effect of ESA use may have been the result of potential protopathic bias (or reverse causality), where an ESA has been prescribed for an early manifestation of cancer that has not been formerly detected and diagnosed. To avoid this potential bias, exposure was assessed at least 6 months prior to the initial diagnosis of cancer [32] . An extended lag-time period prior to identification of cases could limit this bias, but would in turn reduce the number of eligible cases, leading to insufficient power. This is the rationale behind a recommended 6-month lag time [32] . In addition, the surveillance period was short and prior history of cancer was unknown. We were limited to a 2-year window before dialysis initiation to assess prior history of cancer, which may have misidentified new cancer cases from relapses of previous diagnoses. We could not properly assess the risk for each different type of cancer because of statistical power issues. Hemoglobin targets have changed over the last decade and it is possible that lower doses are used more frequently in the present system. Aside from the fact that the high-dose group would be smaller, this phenomenon should not have greatly altered our results. We were also unable to differentiate between administration routes (intravenous versus subcutaneous). While doses may slightly differ by administration route, this nondifferential misclassification error should only attenuate the effect. Finally, our study was not designed to evaluate mortality. The results demonstrated a higher risk of cancer associated with the use of high ESA doses among chronic hemodialysis patients with no history of cancer, after adjusting for several relevant clinical variables. The higher likelihood of malignancies persisted while using a different conversion ratio between epoetin alfa and darbepoetin alfa. This association between cancer and high ESA dose can be further tested through another prospective trial to confirm the validity of our results. While our findings suggest that high-dose ESAs may increase the risk of cancer, further investigation is required to determine whether this association is specific to different types of cancer and whether other factors (e.g. previous exposure to immunosuppressive therapy) may play a role. 
